SG11201701809UA - Cancer cell-specific antibody, anticancer drug and cancer testing method - Google Patents

Cancer cell-specific antibody, anticancer drug and cancer testing method

Info

Publication number
SG11201701809UA
SG11201701809UA SG11201701809UA SG11201701809UA SG11201701809UA SG 11201701809U A SG11201701809U A SG 11201701809UA SG 11201701809U A SG11201701809U A SG 11201701809UA SG 11201701809U A SG11201701809U A SG 11201701809UA SG 11201701809U A SG11201701809U A SG 11201701809UA
Authority
SG
Singapore
Prior art keywords
cancer
specific antibody
testing method
anticancer drug
cancer cell
Prior art date
Application number
SG11201701809UA
Other languages
English (en)
Inventor
Yasuhiro Matsumura
Masahiro Yasunaga
Shinji Saijou
Shingo Hanaoka
Original Assignee
Nat Cancer Ct
Rin Inst Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nat Cancer Ct, Rin Inst Inc filed Critical Nat Cancer Ct
Publication of SG11201701809UA publication Critical patent/SG11201701809UA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57419—Specifically defined cancers of colon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
SG11201701809UA 2014-09-08 2015-09-08 Cancer cell-specific antibody, anticancer drug and cancer testing method SG11201701809UA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2014182760 2014-09-08
JP2014260727 2014-12-24
PCT/JP2015/075425 WO2016039321A1 (ja) 2014-09-08 2015-09-08 がん細胞特異的な抗体、抗がん剤、及びがんの検査方法

Publications (1)

Publication Number Publication Date
SG11201701809UA true SG11201701809UA (en) 2017-04-27

Family

ID=55459067

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201701809UA SG11201701809UA (en) 2014-09-08 2015-09-08 Cancer cell-specific antibody, anticancer drug and cancer testing method

Country Status (12)

Country Link
US (2) US10471146B2 (ja)
EP (1) EP3192527A4 (ja)
JP (2) JP6781507B2 (ja)
KR (1) KR102029248B1 (ja)
CN (1) CN106999576B (ja)
AU (2) AU2015313268B2 (ja)
CA (1) CA2960466C (ja)
IL (1) IL250848B (ja)
MY (1) MY187050A (ja)
RU (1) RU2753512C2 (ja)
SG (1) SG11201701809UA (ja)
WO (1) WO2016039321A1 (ja)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6958817B2 (ja) * 2016-03-08 2021-11-02 国立研究開発法人国立がん研究センター 抗ｔｍｅｍ−１８０抗体、抗がん剤、及びがんの検査方法
CN109641964A (zh) 2016-08-15 2019-04-16 国立研究开发法人国立癌症研究中心 与tmem132a结合的抗体、抗癌剂、以及癌症检查方法
AU2018245602B2 (en) 2017-03-31 2021-07-22 Hirotsu Bio Science Inc. Method for predicting therapeutic effect and/or recurrence monitoring in cancer patients
GB201710835D0 (en) 2017-07-05 2017-08-16 Ucl Business Plc ROR1 Antibodies
GB201710838D0 (en) 2017-07-05 2017-08-16 Ucl Business Plc Bispecific antibodies
GB201710836D0 (en) * 2017-07-05 2017-08-16 Ucl Business Plc ROR1 Car T-Cells
WO2019136300A2 (en) * 2018-01-05 2019-07-11 Immunext, Inc. Anti-mct1 antibodies and uses thereof
WO2021087114A1 (en) * 2019-10-29 2021-05-06 University Of Florida Research Foundation, Incorporated Anti-angiopoietin-like 4 (angptl4) antibodies and methods of use
WO2022098662A2 (en) * 2020-11-03 2022-05-12 Twist Bioscience Corporation Methods and compositions relating to chemokine receptor variants
WO2023105087A1 (en) * 2021-12-10 2023-06-15 Tubulis Gmbh Novel flt3 antibodies and antibody-drug-conjugates based thereon, therapeutic methods and uses thereof in combination with tyrosine kinase inhibitors
CN116769729B (zh) * 2023-06-05 2024-07-02 中国科学技术大学 靶向cd150的抗体或抗原结合片段及其应用
CN117567635B (zh) * 2024-01-16 2024-05-14 恺佧生物科技(上海)有限公司 抗Cas9酶的抗体及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009045201A1 (en) * 2006-08-02 2009-04-09 Biogen Idec Ma Inc. Cancer stem cells
TW201008574A (en) * 2008-08-19 2010-03-01 Oncotherapy Science Inc INHBB epitope peptides and vaccines containing the same
CN102216452B (zh) * 2008-09-26 2013-08-21 尤里卡治疗公司 具有变异糖基化方式的细胞系和蛋白质
EP2177615A1 (en) 2008-10-10 2010-04-21 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Method for a genome wide identification of expression regulatory sequences and use of genes and molecules derived thereof for the diagnosis and therapy of metabolic and/or tumorous diseases
CN102378766A (zh) * 2009-03-23 2012-03-14 夸克医药公司 治疗癌症和纤维化疾病的化合物组合物和方法
US20110195848A1 (en) * 2010-01-08 2011-08-11 Roopra Avtar S Gene expression and breast cancer
AU2011313596A1 (en) * 2010-10-05 2013-04-11 Daiichi Sankyo Company, Limited Antibody targeting osteoclast-related protein Siglec-15
JP5747283B2 (ja) 2012-03-06 2015-07-15 株式会社オーダーメードメディカルリサーチ がん治療用医薬組成物
EP2895864B1 (en) * 2012-09-17 2021-03-10 AIT Austrian Institute of Technology GmbH Colon cancer diagnostic method and means
JP6958817B2 (ja) * 2016-03-08 2021-11-02 国立研究開発法人国立がん研究センター 抗ｔｍｅｍ−１８０抗体、抗がん剤、及びがんの検査方法

Also Published As

Publication number Publication date
JP2021019616A (ja) 2021-02-18
CA2960466C (en) 2023-09-05
AU2015313268A1 (en) 2017-03-23
MY187050A (en) 2021-08-27
EP3192527A4 (en) 2018-04-11
US20170260284A1 (en) 2017-09-14
BR112017004446A2 (ja) 2018-02-27
IL250848A0 (en) 2017-04-30
WO2016039321A1 (ja) 2016-03-17
JP6980075B2 (ja) 2021-12-15
RU2017111584A (ru) 2018-10-10
CN106999576B (zh) 2021-09-03
AU2015313268B2 (en) 2018-12-20
IL250848B (en) 2022-07-01
US20200078458A1 (en) 2020-03-12
RU2017111584A3 (ja) 2018-10-10
US11524074B2 (en) 2022-12-13
CN106999576A (zh) 2017-08-01
EP3192527A1 (en) 2017-07-19
AU2018274932B2 (en) 2020-11-05
RU2753512C2 (ru) 2021-08-17
US10471146B2 (en) 2019-11-12
JP6781507B2 (ja) 2020-11-04
KR20170047351A (ko) 2017-05-04
KR102029248B1 (ko) 2019-10-08
AU2018274932A1 (en) 2019-01-03
CA2960466A1 (en) 2016-03-17
JPWO2016039321A1 (ja) 2017-06-22

Similar Documents

Publication Publication Date Title
IL304772A (en) Antibodies, uses and methods
ZA201806576B (en) Antibodies, pharmaceutical compositions and methods
SG11201701809UA (en) Cancer cell-specific antibody, anticancer drug and cancer testing method
IL252015A0 (en) Antibody drug conjugates
IL251938A0 (en) Antibodies against CS1 and antibody-drug conjugates
IL250189A0 (en) Anti–cdh6 antibody drug conjugates
EP3150707A4 (en) Pancreatic cancer detection kit, device, and detection method
EP3193892A4 (en) Personalized cancer vaccines and methods therefor
SG11201608605QA (en) Methods and means for enhancing rna production
PL3110975T3 (pl) Metody analizy somatycznych elementów ruchomych i ich zastosowania
HK1223562A1 (zh) 配體-細胞毒性藥物偶聯物、其製備方法及其應用
IL252430A0 (en) Antibodies, uses and methods
HUE049533T2 (hu) Polikarbonát kopolimer és eljárás annak elõállítására
SG10202006863YA (en) Cl and/or ch1 mutated antibodies for drug conjugation
EP3395366C0 (en) METHOD FOR DESIGNING A DRUG, DRUG OBTAINED AND ASSOCIATED APPLICATION
SG11201702076WA (en) Cancer evaluation method and cancer evaluation system
LU92659B1 (en) Glycooptimized antibody drug conjugates
EP3134545A4 (en) Method and biomarker for detecting cancer
HK1231405A1 (zh) 篩選和檢測癌症的方法和組成
EP3434765A4 (en) ANTI-TMEM-180 ANTIBODIES, ANTI-STEM AND TREATMENT FOR CANCER
GB201405715D0 (en) Methods, apparatus and materials
EP3184635A4 (en) Cancer marker and cancer determination method
EP3122375A4 (en) Breast and ovarian cancer vaccines
SG11201702260RA (en) Anti-cancer agent and cancer cell killing method
IL257514A (en) A method for detecting cancer